Accumulating evidence indicates that co-inhibitory molecules, such as CTLA-4, PD1, and BTLA, are negative regulators of immune responses since deficiencies or mutations result in the development of autoimmune diseases. This evidence concerns the gene BTLA and autoimmune disease.